Interferons and Their Applications

  • Paul E. Came
  • William A. Carter

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 71)

Table of contents

  1. Front Matter
    Pages I-XXIV
  2. S. E. Grossberg, P. M. Jameson, J. J. Sedmak
    Pages 23-43
  3. D. Gillespie, E. Pequignot, W. A. Carter
    Pages 45-63
  4. P. B. Sehgal, A. D. Sagar
    Pages 65-77
  5. K. C. Zoon, R. Wetzel
    Pages 79-100
  6. H. Smith-Johannsen, Y-T. Hou, X-Y. Liu, Y-H. Tan
    Pages 101-135
  7. J. L. Taylor, J. L. Sabran, S. E. Grossberg
    Pages 169-204
  8. P. I. Marcus
    Pages 205-232
  9. N. B. Finter, K. H. Fantes
    Pages 271-286
  10. J. A. Georgiades, S. Baron, W. R. Fleischmann Jr., M. Langford, D. A. Weigent, G. J. Stanton
    Pages 305-337
  11. P. K. Weck, P. E. Came
    Pages 339-355
  12. J. C. Petricciani, E. C. Esber, H. E. Hopps, A. Attallah
    Pages 357-370
  13. D. A. Stringfellow
    Pages 371-383
  14. D. R. Strayer, W. A. Carter
    Pages 385-402

About this book

Introduction

Today, the basic mood of researchers and clinical investigators, both at the center and on the periphery of interferon studies, is optimistic regarding the future of interferons as therapeutic substances. Many also feel these polypeptides will prove invaluable probes in unraveling certain fundamental biochemical processes which control the life cycle and developmental pattern of many human cells. In contrast, only a year or two ago, this optimism had given way to an attitude almost of disenchantment as public and scientific expectations were raised steeply, then rapidly waned, as it turns out, prematurely. Both the mUltiple actions of interferons (a virtual cascade of biochemical reactions may be induced, as documented herein) and the high visibility of interferon research provided by the millions of dollars invested both by national health agencies and by multinational pharmaceutical companies, contributed to an upsweep in public attention to drug development probably unprecedented in this century. Virtually every oncologist, it would seem, was plagued by requests for the experimental agent, although they already had therapies of more proven value. As recently as 1980, even though interferon had achieved success against certain cancers and certain viral diseases, the variability in clinical results was seemingly ever present and little evidence emerged to suggest interferons could cure advanced diseases. Why then the resurgence of an optimistic mood? There are almost always many elements which contribute to happiness, and this is certainly true of the broad frontier of interferon and its place in biochemical research and treatment.

Keywords

Histamin Hormone Insulin Prostaglandin Vitamin A antibody antigen cancer chromatography hepatitis interferon pharmacokinetics pharmacology research toxicology

Editors and affiliations

  • Paul E. Came
    • 1
  • William A. Carter
    • 2
    • 3
  1. 1.HEM Research Inc.RockvilleUSA
  2. 2.Clinical Research, Department of OncologyOrlowitz Cancer InstitutePhiladelphiaUSA
  3. 3.Department of Hematology and OncologyHahnemann University of Health SciencesPhiladelphiaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-69178-2
  • Copyright Information Springer-Verlag Berlin Heidelberg 1984
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-69180-5
  • Online ISBN 978-3-642-69178-2
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • About this book
Industry Sectors
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods
Pharma